Imagabalin

Imagabalin
Clinical data
Other names	PD-0332334; PD-332,334
ATC code	None;
Identifiers
	IUPAC name (3S,5R)-3-amino-5-methyloctanoic acid;
CAS Number	610300-07-7 ; 610300-00-0 (hydrochloride);
PubChem CID	10236037;
ChemSpider	8411525;
UNII	NDG6931B7H;
KEGG	D09627;
CompTox Dashboard (EPA)	DTXSID00976534 ;
Chemical and physical data
Formula	C9H19NO2
Molar mass	173.256 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)C[C@@H](N)C[C@@H](CCC)C;
	InChI InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1; Key:JXEHXYFSIOYTAH-SFYZADRCSA-N;

Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acts as a ligand for the α₂δ subunit of the voltage-dependent calcium channel, with some selectivity for the α₂δ₁ subunit over α₂δ₂. It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.